Inventiva S.A. (IVA.PA)
EUR 2.15
(2.38%)
EUR 2.15
(2.38%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -110.42 Million EUR | -103.46% |
| 2022 | -54.27 Million EUR | -9.34% |
| 2021 | -49.63 Million EUR | -56.96% |
| 2020 | -31.62 Million EUR | -4.64% |
| 2019 | -30.22 Million EUR | 10.1% |
| 2018 | -33.61 Million EUR | -95.11% |
| 2017 | -17.22 Million EUR | -144.56% |
| 2016 | -7.04 Million EUR | 20.15% |
| 2015 | -8.82 Million EUR | -17.74% |
| 2014 | -7.49 Million EUR | -5.03% |
| 2013 | -7.13 Million EUR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -49.02 Million EUR | 0.0% |
| 2023 Q2 | -55.26 Million EUR | 0.0% |
| 2023 FY | -110.42 Million EUR | -103.46% |
| 2023 Q4 | -55.15 Million EUR | 0.0% |
| 2022 Q4 | -24.8 Million EUR | 0.0% |
| 2022 Q2 | -29.46 Million EUR | 0.0% |
| 2022 FY | -54.27 Million EUR | -9.34% |
| 2021 Q2 | -14.29 Million EUR | -61.74% |
| 2021 Q1 | -8.83 Million EUR | 50.79% |
| 2021 FY | -49.63 Million EUR | -56.96% |
| 2021 Q4 | -26.49 Million EUR | 0.0% |
| 2020 FY | -31.62 Million EUR | -4.64% |
| 2020 Q1 | -6.79 Million EUR | 29.71% |
| 2020 Q2 | -8.87 Million EUR | -30.55% |
| 2020 Q4 | -17.96 Million EUR | 0.0% |
| 2019 FY | -30.22 Million EUR | 10.1% |
| 2019 Q4 | -9.67 Million EUR | 0.0% |
| 2019 Q2 | -20.54 Million EUR | -171.94% |
| 2019 Q1 | -7.55 Million EUR | 55.12% |
| 2018 Q4 | -16.83 Million EUR | 0.0% |
| 2018 FY | -33.61 Million EUR | -95.11% |
| 2018 Q2 | -16.18 Million EUR | -92.54% |
| 2018 Q1 | -8.4 Million EUR | 9.65% |
| 2017 FY | -17.22 Million EUR | -144.56% |
| 2017 Q1 | -4.3 Million EUR | -45.52% |
| 2017 Q2 | -9.78 Million EUR | -127.09% |
| 2017 Q4 | -9.3 Million EUR | 0.0% |
| 2016 Q4 | -2.95 Million EUR | 0.0% |
| 2016 Q2 | -4.08 Million EUR | -131.94% |
| 2016 Q1 | -1.76 Million EUR | 58.54% |
| 2016 FY | -7.04 Million EUR | 20.15% |
| 2015 FY | -8.82 Million EUR | -17.74% |
| 2015 Q4 | -4.24 Million EUR | -92.57% |
| 2015 Q3 | -2.2 Million EUR | 51.79% |
| 2015 Q2 | -4.57 Million EUR | -107.43% |
| 2015 Q1 | -2.2 Million EUR | 0.0% |
| 2014 FY | -7.49 Million EUR | -5.03% |
| 2014 Q2 | -1.87 Million EUR | 0.0% |
| 2014 Q1 | -1.87 Million EUR | 0.0% |
| 2014 Q3 | -1.87 Million EUR | 0.0% |
| 2014 Q4 | -2.2 Million EUR | -17.74% |
| 2013 Q3 | -1.78 Million EUR | 0.0% |
| 2013 Q1 | -1.78 Million EUR | 0.0% |
| 2013 Q4 | -1.87 Million EUR | -5.03% |
| 2013 FY | -7.13 Million EUR | 0.0% |
| 2013 Q2 | -1.78 Million EUR | 0.0% |
| 2012 Q4 | -1.78 Million EUR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| ABIONYX Pharma SA | -3.51 Million EUR | -3038.886% |
| ABIVAX Société Anonyme | -147.74 Million EUR | 25.257% |
| Adocia SA | -21.16 Million EUR | -421.813% |
| Aelis Farma SA | -5.07 Million EUR | -2074.596% |
| Biophytis S.A. | -17.02 Million EUR | -548.573% |
| Advicenne S.A. | -7.03 Million EUR | -1470.559% |
| genOway Société anonyme | 1.56 Million EUR | 7144.384% |
| IntegraGen SA | -171.39 Thousand EUR | -64326.28% |
| Medesis Pharma S.A. | -3.95 Million EUR | -2688.894% |
| Neovacs S.A. | -8.74 Million EUR | -1162.957% |
| NFL Biosciences SA | -3.74 Million EUR | -2848.25% |
| Plant Advanced Technologies SA | 79.16 Thousand EUR | 139581.363% |
| Quantum Genomics Société Anonyme | -3.17 Million EUR | -3382.43% |
| Sensorion SA | -22.06 Million EUR | -400.494% |
| Theranexus Société Anonyme | -6.82 Million EUR | -1517.264% |
| TME Pharma N.V. | -6.73 Million EUR | -1539.341% |
| Valbiotis SA | -7.36 Million EUR | -1398.724% |
| TheraVet SA | -1.57 Million EUR | -6930.337% |
| Valerio Therapeutics Société anonyme | -20.34 Million EUR | -442.794% |
| argenx SE | -272.91 Million EUR | 59.538% |
| BioSenic S.A. | -28.77 Million EUR | -283.717% |
| Celyad Oncology SA | -8.44 Million EUR | -1207.126% |
| DBV Technologies S.A. | -67.26 Million EUR | -64.155% |
| Galapagos NV | 211.69 Million EUR | 152.162% |
| Genfit S.A. | -28.89 Million EUR | -282.176% |
| GeNeuro SA | -14.75 Million EUR | -648.296% |
| Hyloris Pharmaceuticals SA | -15.38 Million EUR | -617.984% |
| Innate Pharma S.A. | -7.57 Million EUR | -1358.732% |
| MaaT Pharma SA | -19.71 Million EUR | -460.055% |
| MedinCell S.A. | -25.03 Million EUR | -341.034% |
| Nanobiotix S.A. | -39.7 Million EUR | -178.151% |
| Onward Medical N.V. | -36.18 Million EUR | -205.204% |
| Oryzon Genomics S.A. | -3.35 Million EUR | -3193.405% |
| OSE Immunotherapeutics SA | -23 Million EUR | -380.05% |
| Oxurion NV | -18.96 Million EUR | -482.139% |
| Pharming Group N.V. | -9.75 Million EUR | -1031.81% |
| Poxel S.A. | -35.09 Million EUR | -214.694% |
| GenSight Biologics S.A. | -26.22 Million EUR | -321.152% |
| Transgene SA | -22.32 Million EUR | -394.563% |
| Financière de Tubize SA | 88.15 Million EUR | 225.269% |
| UCB SA | 343 Million EUR | 132.194% |
| Valneva SE | -101.42 Million EUR | -8.87% |
| Vivoryon Therapeutics N.V. | -28.34 Million EUR | -289.62% |